boston pharmaceuticals - Search News

Order byBest matchMost fresh

News

GSK to buy phase III-ready drug efimosfermin

GSK buys liver drug from Boston Pharmaceuticals for up to $2 billion

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the promising field of liver therapies.

Continue reading

GSK to buy experimental MASH drug for $1.2B upfront

· 18h · on MSN

GSK to buy phase III-ready drug efimosfermin from Boston Pharmaceuticals for as much as $2B

19h

GSK to buy efimosfermin for up to $2 billion

GSK will buy efimosfermin, a specialty medicine used to treat liver disease from Boston Pharmaceuticals, for up to $2 billion ...

Once-Monthly Efimosfermin Leads to Significant MASH Improvement in Phase 2 Trial

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results